skip to content

Department of Pathology



Caroline is the Academic Director for Cambridge-Africa. She is a Principal Research Associate in Epidemiology at the University of Cambridge and an honorary epidemiologist at Public Health England. Her research examines the potential and actual impact of immunisation using a range of methods from classic epidemiology to mathematical modelling and health economics. Her work has been used to inform national and, as a consultant to the World Health Organisation, international vaccine policy. Much of Caroline's research is focussed on meningococcal disease and carriage in the UK and Africa, working with African partners, including the African Meningococcal Carriage Consortium (MenAfriCar). She has been involved in a range of projects in the African meningitis belt, both to quantify the impact of MenAfriVac (an affordable group A meningococcal conjugate vaccine), and to investigate both short (epidemic response) and long-term (preventive vaccination) options for the control of epidemic meningitis. She also has current projects on the impact of vaccination against group B streptococcus and rabies.




Key publications: 

WHO Rabies Modelling Consortium (Corresponding authors Trotter CL, Hampson K). The potential impact of improved provision of rabies post-exposure prophylaxis in Gavi-eligible countries: a modelling study. Lancet Infectious Diseases, 2018, Nov 21. pii: S1473-3099(18)30512-7. doi: 10.1016/S1473-3099(18)30512-7

Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Preziosi MP, Stuart JM. The impact of MenAfriVac in nine countries of the African meningitis belt, 2010-2015: an analysis of surveillance data. Lancet Infect Dis 2017, pii: S1473-3099(17)30301-8

Karachaliou A, Conlan AJ, Preziosi MP, Trotter CL. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt. Clin Infect Dis. 2015;61 Suppl 5:S594-600. 

MenAfriCar Consortium. The diversity of meningococcal carriage across the African meningitis belt and the impact of vaccination with a group A meningococcal conjugate vaccine. J Infect Dis 2015.  doi: 10.1093/infdis/jiv211
Christensen H, Trotter CL, Hickman M, Edmunds WJ. Re-evaluating the cost-effectiveness of universal ‘MenB’ (Bexsero) vaccination in England: a modelling study. BMJ2014  349